Clinical Research Directory
Browse clinical research sites, groups, and studies.
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
Sponsor: University of Colorado, Denver
Summary
This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.
Key Details
Gender
All
Age Range
18 Years - 49 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-06-21
Completion Date
2027-12-01
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
Semaglutide Pen Injector
Semaglutide injection
Placebo
Semaglutide placebo injection
Locations (2)
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
University of Washington Medicine Diabetes Institute (UWMDI)
Seattle, Washington, United States